Menu Search
Equities

ReWalk Robotics Ltd

2RW:MUN

ReWalk Robotics Ltd

Actions
  • Price (EUR)4.81
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change+22.80%
  • Beta--
Data delayed at least 15 minutes, as of Apr 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ReWalk Robotics Ltd. doing business as Lifeward is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.

  • Revenue in USD (TTM)17.91m
  • Net income in USD-24.09m
  • Incorporated2001
  • Employees108.00
  • Location
    ReWalk Robotics Ltd3 Hatnufa st. 6th fl.,P.O. Box 161YOKNEAM 2069203IsraelISR
  • Phone+972 49590123
  • Websitehttps://golifeward.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		2RW:FRA since
announced		Transaction
value
AlterG IncDeal completed08 Aug 202308 Aug 2023Deal completed-4.53%19.00m
Data delayed at least 15 minutes, as of Mar 18 2024.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.